Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01144988 : Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

1. Patients present with a first or second tumor recurrence / progression of a
histological confirmed supratentorial malignant glioma WHO Grade III-IV
(Classification following WHO criteria).

2. Patients with surgical resection of tumor recurrence / progression: Following
standard therapy(first recurrence) or standard therapy / second line chemotherapy
(second recurrence, excepting antiangiogenic approaches) patients must have evidence
of further tumor progression measured by standard MRI sequences (MacDonald criteria).
If possible, patients may have prior surgical resection of the tumor progression and
will be eligible if the following conditions apply:

- Patients must have recovered from the effects of surgery

- To adequately asses the malignant glioma before surgery and the extent of
residual disease postoperatively, two MRIs scans have to be performed:

- A first standard MRI scan has to be done within 1 week before surgery to
document a progressed or recurrent malignant glioma.

- A second standard / functional MRI scan has to be done between 24 and 48 hours
after surgery to document the postoperative malignant glioma (Baseline MRI

- FET- / FLT-PET scans have to be done within 2 weeks after surgery to document
the postoperative malignant glioma (Baseline PET scans).

Patients without surgical resection of the tumor recurrence / progression: Patients
must have evidence of tumor progression measured by standard MRI sequences (MacDonald

- Additional functional MRI sequences have to be done within 1 week prior to study

- FET- / FLT-PET scans have to be done within 2 weeks after surgery to document
the postoperative malignant glioma (Baseline PET scans).

3. Resolution of all acute toxic effects of prior therapy to grade ? 1 (except alopecia)

4. Patients must have an ECOG performance status of 0-2

5. Patients must be ? 18 years and ? 80 years of age, with a life expectancy of greater
than 8 weeks

6. Patients must have adequate organ function as defined by the following criteria:

Bone Marrow Reserve

- Platelets ? 75.000/?L

- Absolute Neutrophil Count ? 1500/?L

- Hemoglobin ? 10.0 g/dL Blood Coagulation

- aPTT ? 1.5 times upper limit of normal (ULN) Hepatic Function

- ASAT and ALAT ? 2.5 times ULN

- ALP ? 2.5 times ULN

- Total SERUM Bilirubin < 1.5 times ULN Renal Function

- SERUM Creatinine ? 1.5 times ULN Metabolism

- SERUM Albumin ? 3.0 g/dL All tests must be performed ? 3 days prior to study
enrollment. Eligibility for hemoglobin count may be reached by transfusion.

7. Signed and dated informed consent document by the patient, indicating that the
patient has been informed of all the pertinent aspects of the trial prior to study

8. Willingness and ability of the patient to comply with scheduled visits, treatment
plans, laboratory tests, and other study procedures.

Exclusion Criteria:

9. The patient is active participant in another clinical trial, which investigates
substances with antiangiogenic effectiveness

10. Exclusion of patients in the event of

- surgery of a recurrent / progressed malignant glioma within 2 weeks prior to
study enrollment

- chemotherapy (Standard therapy o Second Line Chemotherapy) within 2 weeks prior
to study enrollment

- radiation therapy (Standard therapy) within4 weeks to study enrollment

- evidence in baseline MRI of intratumoral or peritumoral hemorrhage deemed
clinically significant by the treating physician (area of hemorrhage > 25% of
tumor area)

11. Significant Co-Morbidities within 12 months prior to study enrollment

- myocardial infarction, severe/unstable angina pectoris, coronary/peripheral
artery bypass graft, congestive heart failure

- cerebrovascular accident including transient ischemic attack

12. Significant Co-Morbidities at Baseline Evaluation

- Hypertension that cannot be controlled by medications (>150/100 mmHg despite
optimal medical therapy)

- Pulmonary embolism within 4 weeks before study enrollment

- A known HIV (human immunodeficiency virus) or Hepatitis B/C infection or severe
acute infection

13. Anticoagulation: Current treatment with therapeutic doses of Marcoumar / Sintrom
excluding thrombosis prophylaxis with low dose Heparin

14. Pregnancy, Breastfeeding and Non-Contraception

- Female patients who are pregnant or nursing

- Patients who are sexually active and unwilling or unable to use a medically
acceptable method of contraception during the trial

15. Evidence of increased intracranial pressure

- midline shift > 5 mm

- headache, distinct nausea and vomiting

16. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that would impart excess risk associated with study participation or
study drug administration, or which would make the patient inappropriate for entry
into this study. The decision to enroll the patient in this study is in the judgment
of the investigator.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557